UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 107

Sortiert nach

Rescue of Hippo coactivator YAP1 triggers DNA damage-induced apoptosis in hematological cancers

Nature medicine, 2014-06, Vol.20 (6), p.599-606

2014

Link zum Volltext

Verfügbarkeit prüfen

Random Evolution Equations: Well-Posedness, Asymptotics, and Applications to Graphs

Applied mathematics & optimization, 2021-12, Vol.84 (3), p.2849-2887

2021

Link zum Volltext

Verfügbarkeit prüfen

Understanding DNA Damage Response and DNA Repair in Multiple Myeloma

Cancers, 2023-08, Vol.15 (16), p.4155

2023

Link zum Volltext

Verfügbarkeit prüfen

Discovery of selective small-molecule HDAC6 inhibitor for overcoming proteasome inhibitor resistance in multiple myeloma

Proceedings of the National Academy of Sciences - PNAS, 2016-11, Vol.113 (46), p.13162-13167

2016

Link zum Volltext

Verfügbarkeit prüfen

Synthetic Lethal Approaches Exploiting DNA Damage in Aggressive Myeloma

Cancer discovery, 2015-09, Vol.5 (9), p.972-987

2015

Link zum Volltext

Verfügbarkeit prüfen

CD56 expression predicts response to Daratumumab-based regimens

Blood cancer journal (New York), 2024-04, Vol.14 (1), p.62-62

2024

Link zum Volltext

Verfügbarkeit prüfen

Targeting NAD+ salvage pathway induces autophagy in multiple myeloma cells via mTORC1 and extracellular signal-regulated kinase (ERK1/2) inhibition

Blood, 2012-10, Vol.120 (17), p.3519-3529

2012

Link zum Volltext

Verfügbarkeit prüfen

Concomitant 1q+ and t(4;14) influences disease characteristics, immune system, and prognosis in double-hit multiple myeloma

Blood cancer journal (New York), 2023-11, Vol.13 (1), p.167-167, Article 167

2023

Link zum Volltext

Verfügbarkeit prüfen

Selective and Potent Akt Inhibition Triggers Anti-Myeloma Activities and Enhances Fatal Endoplasmic Reticulum Stress Induced by Proteasome Inhibition

Cancer research (Chicago, Ill.), 2014-08, Vol.74 (16), p.4458-4469

2014

Link zum Volltext

Verfügbarkeit prüfen

p53-related protein kinase confers poor prognosis and represents a novel therapeutic target in multiple myeloma

Blood, 2017-03, Vol.129 (10), p.1308-1319

2017

Link zum Volltext

Verfügbarkeit prüfen

Impact of interval progression before autologous stem cell transplant in patients with multiple myeloma

Frontiers in oncology, 2023, Vol.13, p.1216461-1216461

2023

Link zum Volltext

Verfügbarkeit prüfen

Real World Experience of Daratumumab: Evaluating Lymphopenia and Adverse Events in Multiple Myeloma Patients

Frontiers in oncology, 2021-02, Vol.10, p.575168-575168

2021

Link zum Volltext

Verfügbarkeit prüfen

Racial differences as predictors of outcomes in young patients with multiple myeloma

Blood cancer journal (New York), 2022-07, Vol.12 (7), p.114-114, Article 114

2022

Link zum Volltext

Verfügbarkeit prüfen

Improvement in Post-Autologous Stem Cell Transplant Survival of Multiple Myeloma Patients: A Long-Term Institutional Experience

Cancers, 2022-05, Vol.14 (9), p.2277

2022

Link zum Volltext

Verfügbarkeit prüfen

To be or not to be: the role of CD56 in multiple myeloma

Oncotarget, 2023-01, Vol.14 (1), p.47-49

2023

Link zum Volltext

Verfügbarkeit prüfen

Combination of a Selective HSP90α/β Inhibitor and a RAS-RAF-MEK-ERK Signaling Pathway Inhibitor Triggers Synergistic Cytotoxicity in Multiple Myeloma Cells

PloS one, 2015-12, Vol.10 (12), p.e0143847-e0143847

2015

Link zum Volltext

Verfügbarkeit prüfen

Delineating the mTOR kinase pathway using a dual TORC1/2 inhibitor, AZD8055, in multiple myeloma

Molecular cancer therapeutics, 2014-11, Vol.13 (11), p.2489-2500

2014

Link zum Volltext

Verfügbarkeit prüfen

Characterization of monoclonal gammopathy of undetermined significance progression to multiple myeloma through meta-analysis of GEO data

Heliyon, 2023-07, Vol.9 (7), p.e17298-e17298, Article e17298

2023

Link zum Volltext

Verfügbarkeit prüfen

Incidence, Treatment, and Survival of Patients With T-Cell Lymphoma, T-Cell Large Granular Leukemia, and Concomitant Plasma Cell Dyscrasias

Frontiers in oncology, 2022-04, Vol.12, p.858426-858426

2022

Link zum Volltext

Verfügbarkeit prüfen

Early versus Late Discontinuation of Maintenance Therapy in Multiple Myeloma

Journal of clinical medicine, 2022-09, Vol.11 (19), p.5794

2022

Link zum Volltext

Verfügbarkeit prüfen

Multiple Myeloma: Clinical Updates from the American Society of Clinical Oncology Annual Scientific Symposium 2020

Journal of clinical medicine, 2020-11, Vol.9 (11), p.3626

2020

Link zum Volltext

Verfügbarkeit prüfen

Gaussian limits for subcritical chaos

Electronic journal of probability, 2022-01, Vol.27 (none)

2022

Link zum Volltext

Verfügbarkeit prüfen

Novel therapeutic targets in multiple myeloma

Clinical advances in hematology & oncology, 2015-04, Vol.13 (4), p.236-248

2015

Link zum Volltext

Verfügbarkeit prüfen

Redefining CD56 as a biomarker and therapeutic target in Multiple Myeloma

Molecular cancer research, 2022-07, Vol.20 (7), p.1083-1095

2022

Link zum Volltext

Verfügbarkeit prüfen

Histone deacetylase 3 as a novel therapeutic target in multiple myeloma

Leukemia, 2014-03, Vol.28 (3), p.680-689

2014

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 107

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(99)
Mit Volltextzugriff
(94)

Publikationsform

Artikel
(106)
Buchkapitel
(1)

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Rescue of Hippo coactivator YAP1 triggers DNA damage-induced apoptosis in hematological cancers

Random Evolution Equations: Well-Posedness, Asymptotics, and Applications to Graphs

Understanding DNA Damage Response and DNA Repair in Multiple Myeloma

Discovery of selective small-molecule HDAC6 inhibitor for overcoming proteasome inhibitor resistance in multiple myeloma

Synthetic Lethal Approaches Exploiting DNA Damage in Aggressive Myeloma

CD56 expression predicts response to Daratumumab-based regimens

Targeting NAD+ salvage pathway induces autophagy in multiple myeloma cells via mTORC1 and extracellular signal-regulated kinase (ERK1/2) inhibition

Concomitant 1q+ and t(4;14) influences disease characteristics, immune system, and prognosis in double-hit multiple myeloma

Selective and Potent Akt Inhibition Triggers Anti-Myeloma Activities and Enhances Fatal Endoplasmic Reticulum Stress Induced by Proteasome Inhibition

p53-related protein kinase confers poor prognosis and represents a novel therapeutic target in multiple myeloma

Impact of interval progression before autologous stem cell transplant in patients with multiple myeloma

Real World Experience of Daratumumab: Evaluating Lymphopenia and Adverse Events in Multiple Myeloma Patients

Racial differences as predictors of outcomes in young patients with multiple myeloma

Improvement in Post-Autologous Stem Cell Transplant Survival of Multiple Myeloma Patients: A Long-Term Institutional Experience

To be or not to be: the role of CD56 in multiple myeloma

Combination of a Selective HSP90α/β Inhibitor and a RAS-RAF-MEK-ERK Signaling Pathway Inhibitor Triggers Synergistic Cytotoxicity in Multiple Myeloma Cells

Delineating the mTOR kinase pathway using a dual TORC1/2 inhibitor, AZD8055, in multiple myeloma

Characterization of monoclonal gammopathy of undetermined significance progression to multiple myeloma through meta-analysis of GEO data

Incidence, Treatment, and Survival of Patients With T-Cell Lymphoma, T-Cell Large Granular Leukemia, and Concomitant Plasma Cell Dyscrasias

Early versus Late Discontinuation of Maintenance Therapy in Multiple Myeloma

Multiple Myeloma: Clinical Updates from the American Society of Clinical Oncology Annual Scientific Symposium 2020

Gaussian limits for subcritical chaos

Novel therapeutic targets in multiple myeloma

Redefining CD56 as a biomarker and therapeutic target in Multiple Myeloma

Histone deacetylase 3 as a novel therapeutic target in multiple myeloma

Suchergebnisse filtern